November 2010
CMAJ: Canadian Medical Association Journal;11/9/2010, Vol. 182 Issue 16, pE739
Academic Journal
The article offers medical news briefs. It notes the move of the European Medicines Agency and the U.S. Food and Drug Administration (FDA) to place limitations on the use of rosiglitazone for type 2 diabetes treatment because of its elevated risk of cardiovascular events. Results of a study showed that metabolic stress resulting from inadequate oxygen intake may play a role in suicide. The FDA has approved the first oral drug for the treatment of relapsing forms of multiple sclerosis (MS).


Related Articles

  • Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA(tm) (alemtuzumab) for Multiple Sclerosis.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Genzyme Corp. has submitted a supplemental Biologics License Application to the U.S. Food & Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA (alemtuzumab) for treatment of...

  • Merck Serono: Novartis to benefit from MS pill setback.  // PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p5 

    The article reports that European Medicines Agency (EMA) has rejected oral cladribine drug Movectro from Merck Serono SA for multiple sclerosis (MS) treatment. However, the U.S. Food and Drug Administration has approved Gilenya drug from Novartis AG for MS treatment. EMA's Committee for...

  • Gilenya.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article reports on U.S. Food and Drug Administration's (FDA) approval of the use of Gilenya capsules (fingolimod) to reduce relapses and delay progressive disability in patients with multiple sclerosis (MS).

  • New Drug Approved for Multiple Sclerosis.  // Clarendon Enterprise (TX);10/18/2012, Vol. 23 Issue 42, p4 

    The article informs that the U.S. Food and Drug Administration has approved the new drug Aubagio for the treatment of Multiple Sclerosis.

  • FDA APPROVES THREE-TIMES-A-WEEK COPAXONE.  // Medical Economics;3/10/2014, Vol. 91 Issue 5, p12 

    The article reports on the approval given by the U.S. Food and Drug Administration to a supplemental new drug application for three-times-a-week COPAXONE 400 milligram/milliliter, a new dose of COPAXONE for patients with relapsing forms of multiple sclerosis.

  • FDA Panel Backs Novartis Oral MS Drug Gilenia.  // Bioworld Week;6/21/2010, Vol. 18 Issue 25, p2 

    The article reports that Novartis AG's Gilenia, known to reduce frequency of exacerbations in multiple sclerosis, was unanimously approved by the U.S. Food and Drug Administration (FDA) panel.

  • Rebif Rebidose to Treat MS.  // Monthly Prescribing Reference;Jan2013, Vol. 29 Issue 1, pA14 

    The article offers information regarding the approval of a drug Rebif Rebidose from Serono Inc. and Pfizer Inc. by the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS).

  • FIRST GENERIC FOR RELAPSING FORMS OF MS.  // Pharmacy Today;May2015, Vol. 21 Issue 5, p21 

    The article informs that the U.S. Food and Drug Administration has approved Copaxone, glatiramer acetate injection, for the treatment of patients with relapsing forms of multiple sclerosis, which is manufactured by pharmaceutical company Sandoz.

  • EMA recommended approval for 40 new drugs in 2014. Mullard, Asher // Nature Reviews Drug Discovery;Feb2015, Vol. 14 Issue 2, p82 

    The article reports on the recommendations for drug approval on 40 new drugs by the European Medicines Agency (EMA) to the U.S. Food and Drug Administration (FDA) for treating patient's with rare diseases.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics